Editor's Note: Green and red arrows refer to intraday stock price movement.


Amgen ( AMGN) upgraded at BofA/Merrill to Neutral from Underperform following a positive survey on the company's two key products, Epogen and Zgeva, Bank of America/Merrill Lynch said. Price target raised to $59 from $56.

Aeroflex ( ARX) rated new Buy at Goldman. $17.50 price target. Company has a strong chip business, with leverage to 4G wireless. Debt paydown could also add to earnings.

Booz Allen Hamilton ( BAH) initiated at BofA/Merrill with a Neutral rating and $22 price target. The government consultant has grown revenue organically at 18% CARG over the past 12 years, Bank of America/Merrill Lynch said.

Sotheby's ( BID) rated new Market Outperform at JMP Securities. $54 price target. Company should see higher demand from Asia and stands to benefit from the current high-end art cycle.

Carnival ( CCL) upgraded at Deutsche from Hold to Buy. $57.50 price target. Company is performing well and keeping a tight lid on costs.

eBay ( EBAY) rated new Neutral at Wedbush Securities. $31 price target. Marketplace revenue continues to lag.

Emergency Medical ( EMS) downgraded at Jefferies from Buy to Hold. Valuation call, based on a $73 price target.

Hawaiian Electric ( HE) upgraded at Baird from Neutral to Outperform. $27 price target. Company should deliver stronger earnings with less volatility.

International Flavors & Fragrances ( IFF) initiated at Credit Suisse with an Outperform rating and $70 price target. Innovation and emerging market customers will drive growth, Credit Suisse said.

Ingersoll Rand ( IR) downgraded at Wells from Outperform to Market Perform. Valuation call.

Martin Marietta ( MLM) downgraded at UBS from Buy to Neutral. $94 price target. Risk/reward is less favorable at current levels, as the company faces cost pressures.

Motorola Mobility ( MMI) rated new Overweight at Morgan Stanley. $36 price target. Company can gain market share and the business will likely shift toward higher-margin Android phones.

Motorola Mobility ( MMI) rated new Buy at Goldman. $37 price target. Company should deliver above-average growth, given its leverage to the smartphone and tablet businesses.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback